A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
about
Acellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenMolecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.Rediscovering PertussisRoads to the development of improved pertussis vaccines paved by immunologyPertussis vaccine trials in the 1990sDirected evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates.Pertussis: Microbiology, Disease, Treatment, and Prevention.Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughsHow to make sense of pertussis immunogenicity data.Production and characterization of recombinant pertactin, fimbriae 2 and fimbriae 3 from Bordetella pertussis.Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.Acellular pertussis vaccine efficacy: An updated systematic review and meta -analysis.Bordetella parapertussis infection in children: epidemiology, clinical symptoms, and molecular characteristics of isolatesAcellular pertussis vaccine protects against exacerbation of allergic asthma due to Bordetella pertussis in a murine model.Above all, do no harm: assessing the risk of an adverse reaction.Haemophilus ducreyi secretes a filamentous hemagglutinin-like protein.A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolutionBordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally.Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adultsDifferential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.Th17 cytokines and vaccine-induced immunity.Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposure.Diagnosis and management of pertussis.Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programsAnalysis of Bordetella pertussis populations in European countries with different vaccination policiesProtective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge modelDevelopment of a recombinant epsilon toxoid vaccine against enterotoxemia and its use as a combination vaccine with live attenuated sheep pox virus against enterotoxemia and sheep pox.Comparison of five commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussisHumoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein.Acellular pertussis vaccines and the role of pertactin and fimbriae.Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.A regulatory role for interleukin 4 in differential inflammatory responses in the lung following infection of mice primed with Th1- or Th2-inducing pertussis vaccines.Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination.Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children.Update on pertussis in children.
P2860
Q24193554-4A19A4E7-5C62-4E11-B9A9-C0E6E9886F2EQ24201103-8918077C-901E-43AC-827D-D568E57E934FQ24234899-6CFBD520-0CBD-4B6D-9C6C-243E9F9C83BBQ24243261-78D47058-7E2C-41C9-B22E-56AD2B484AB4Q24522458-439D4A05-EB2E-4899-ACF7-B1AF0C1F2F4BQ26744793-920A975B-4E35-4C2D-B94A-D06F7B563E8EQ26782939-2D458447-A39B-4BEB-A5BA-3CD9112D85EFQ27025393-0A128891-12A6-40D5-A278-7D31AA2C87F7Q30155406-4ECA14D9-699E-4322-BBF5-8D6BA2B414A0Q30251684-A0C0BD32-8011-4A63-A231-FB089D07D499Q30452542-D66D7CC4-9473-40F5-B6A8-914EE15622FDQ30665598-7AE3AEBE-F852-425B-872E-FDF6AEB62694Q33521111-A99344B1-F232-4B7B-99FD-7BEB0627713BQ33596979-971098E4-7173-4176-A0A8-953635099064Q33642326-13E8DC56-5421-4E80-9EC8-E69B49286610Q33661613-ACD0B7EB-2CF0-4336-A522-69FF7C7704C0Q33716587-543EB52A-387F-4416-8792-D15D50B1C520Q33728888-9DC3A8DB-B5D0-496B-80A1-3787EB643E96Q33741949-3CC9E6EC-95D6-4624-A242-19BD7DB8A6C0Q33750257-D3E781E6-4755-4E57-B4FA-9AC96E68AD0BQ33750402-F2DF2D66-A709-4620-B500-757E638CD100Q33752750-BB74DF6D-60BD-4F60-A2D3-3D612FDF8A93Q33758073-C13CAC63-5C15-452C-8E6F-35DA6ADADAA7Q33784386-5334D5D0-B255-4AF8-A1BB-FDED945FDFD8Q33792227-49A10906-F9D3-45AD-A114-0E9F1001066FQ33813616-0CAAFCB9-AB74-432C-A7CA-2B426DE72CDEQ33833442-1DEE07BF-E9BA-4A87-804A-805D37ECBB23Q33856133-100B68A5-AD56-486F-BAFA-0F7782A76784Q33856228-0D8C20F1-5F2F-4B04-9217-49A2CD65A1B2Q33866775-E8DA4790-0C11-42A4-84D1-3DB84006623AQ33909152-A0F05089-F587-4AC1-BEB2-50771ED0A0CAQ33998364-D2A15047-0E8A-49EB-900E-EA79D5FB5AD7Q34002019-0C930EE5-A1F6-4608-8D70-E2B6CA716D48Q34002283-B3BF4451-CC7A-41B9-ADC5-923A0DBF554EQ34002672-25C95577-9446-4C64-B5AB-FF63C6E0C397Q34003563-701861D6-167B-4B1E-9B9F-F8387F704B74Q34008022-E966D2A7-B559-4F05-B791-D5B5F0EFCEC8Q34008317-E81DEE02-8674-4C57-AD6A-C46FCC2A7A1AQ34013394-9795CF8F-3C0E-4931-8C3B-2E66E36BD83BQ34095301-E4B3306F-952F-452B-AD27-725D243D848F
P2860
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
description
article
@en
im Februar 1996 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 1996
@uk
ലേഖനം
@ml
name
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@en
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@nl
type
label
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@en
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@nl
prefLabel
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@en
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@nl
P2093
P1476
A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis
@en
P2093
Alessandra Anemona
Anna Giammanco
David L. Klein
Donato Greco
Marta L. Ciofi degli Atti
Paola Mastrantonio
Pietro Panei
Stefania Salmaso
Steven G.F. Wassilak
William C. Blackwelder
P304
P356
10.1056/NEJM199602083340601
P407
P577
1996-02-08T00:00:00Z